Anti-Human CD22 Recombinant Antibody (CD22.2) (CAT#: TAB-1722CL)

Figure 1 is a graph shows CD22 ECD binding by anti-CD22 recombinant human antibodies CD22.1 and CD22.2 as compared to that of the 19A3 parent human antibody.

Figure 2 is a graph shows binding of CD22 expressed on the surface of CHO cells by the by anti-CD22 recombinant human antibodies CD22.1 and CD22.2.

Figure 3 is a graph shows binding of CD22 expressed on the surface of Raji cells by the by anti-CD22 recombinant human antibodies CD22.1 and CD22.2.

Figure 4 is a bar graph shows binding of the CD22 ECD amino-terminal domains 1 and 2 by anti-CD22 antibodies 12C5, 19A3, 16F7 and 23C6, and by recombinant human antibodies CD22.1 and CD22.2.

Figure 5 shows the in-vivo effect of antibody-drug conjugates CD22.1-Cytotoxin A and CD22.2-Cytotoxin A on Raji-cell tumor size in SCID mice.

Figure 1 Anti-CD22 Antibody (TAB-1722CL) in Flow Cytometry

Flow cytometry analysis of Daudi cells with anti-CD22 antibody (Cat#TAB-1722CL, Blue line) or isotype control antibody (Yellow line). A Goat Anti-human IgG (FITC) was used as the secondary antibody.

Figure 2 Anti-CD22 Antibody (TAB-1722CL) in ELISA

ELISA analysis of TAB-1722CL was performed by coating with CD22 Protein, Human, Recombinant (His Tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 3 Anti-CD22 Antibody (TAB-1722CL) in WB

Western blot analysis of TAB-1722CL was performed with CD22 Protein, Human, Recombinant (His Tag).
TAB-1722CL incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (0.1 μg)
Lane 2: Reducing antigen (0.3 μg)
Lane 3: Reducing antigen (0.6 μg)